4-溴丁酸酯 | 63099-19-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 4-溴丁酸酯
• 英文名称: 3-Bromomethylpropionate
• 英文别名: 2-bromoethylethanoate；2-bromoethylacetate；4-bromobutanoate；4-bromobutyrate
• CAS: 63099-19-4
• 化学式: C₄H₆BrO₂
• 分子量: 165.994
• InChiKey: GRHQDJDRGZFIPO-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  40.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-溴丁酸酯 在 四甲基氢氧化铵 作用下， 以 二甲基亚砜 为溶剂， 生成 γ-丁内酯
  参考文献：
  名称：

  Ring-closure reactions. 11. The activation parameters for the formation of four- to six-membered lactones from .omega.-bromoalkanoate ions. The role of the entropy factor in small- and common-ring formation

  摘要：

  DOI：

  10.1021/ja00470a032

文献信息

• Indole derivatives useful as testosterone 5.alpha.-reductase inhibitors
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05530019A1

  公开（公告）日：1996-06-25

  A compound of the formula (I): ##STR1## wherein R.sup.1 is an optionally protected carboxy(lower)alkyl, R.sup.2 is a hydrogen, an optionally substituted aryl or a carboxy, X is a bond, --0--, --NH-- or a cycloalkylene, and Y is an alkylene which may be interrupted by an oxygen atom, an alkenylene or an alkadienylene, or a pharmaceutically acceptable salt thereof. The compound of the present invention is useful as a testosterone 5.alpha.-reductase inhibitor and effective against testosterone 5.alpha.-reductase-mediated diseases such as prostatism, prostatic hypertrophy, prostatic cancer, alopecia, hirsutism (e.g. female hirsutism), androgenic alopecia (or male-pattern baldness), acne (e.g. acne vulgaris, pimple), and other hyperandrogenisms.

  化合物的结构式（I）：##STR1## 其中R.sup.1是可选择保护的羧基（较低）烷基，R.sup.2是氢，可选择取代的芳基或羧基，X是键，-0-，-NH-或环烷基，而Y是可被氧原子、烯基或烷二烯基中断的烷基，或其药学上可接受的盐。本发明的化合物可用作睾酮5α-还原酶抑制剂，对睾酮5α-还原酶介导的疾病，如前列腺增生、前列腺肥大、前列腺癌、脱发、多毛症（如女性多毛症）、雄激素性脱发（或男性型脱发）、痤疮（如痤疮、粉刺）和其他高雄激素症有效。
• Amidinoindoles, amidinoazoles, and analogs thereof
  申请人：E. I. du Pont de Nemours and Company

  公开号：US06043257A1

  公开（公告）日：2000-03-28

  The present application describes amidinoindoles, amidinoazoles, and analogs thereof of formula I: ##STR1## wherein W, W.sup.1, W.sup.2, and W.sup.3 are selected from CH and N, provided that one of W.sup.1 and W.sup.2 is C(C(.dbd.NH)NH.sub.2) and at most two of W, W.sup.1, W.sup.2, and W.sup.3 are N and one of J.sup.a and J.sup.b is substituted by --(CH.sub.2).sub.n --Z--A--B, which are useful as inhibitors of factor Xa or thrombin.

  本申请描述了公式I的氨基亚硝基吲哚，氨基咪唑及其类似物：##STR1## 其中W，W.sup.1，W.sup.2和W.sup.3从CH和N中选择，前提是W.sup.1和W.sup.2中的一个是C(C(.dbd.NH)NH.sub.2)，并且W、W.sup.1、W.sup.2和W.sup.3中最多有两个是N，J.sup.a和J.sup.b中的一个被替换为--(CH.sub.2).sub.n --Z--A--B，这些化合物可用作因子Xa或凝血酶的抑制剂。
• Trisubstituted amine compound
  申请人：Nakamura Yoshinori

  公开号：US20090029994A1

  公开（公告）日：2009-01-29

  The present invention relates to a compound of the general formula (1): wherein, Y is a methylene group, and the like; A is an optionally substituted heterocyclic group, and the like; B is an optionally substituted phenyl group, and the like; R 1 is an optionally substituted alkyl group, and the like; and R 2 is an optionally substituted amino group, and the like; or a pharmaceutically acceptable derivative thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP), thereby being useful for prophylaxis and/or treatment of arteriosclerotic diseases, hyperlipemia or dyslipidemia, and the like.

  本发明涉及一般式(1)的化合物，其中Y是亚甲基基团等；A是可选择取代的杂环基团等；B是可选择取代的苯基团等；R1是可选择取代的烷基团等；R2是可选择取代的氨基团等；或其药学上可接受的衍生物，该化合物具有胆固醇酯转移蛋白（CETP）的抑制活性，因此可用于动脉粥样硬化疾病、高脂血症或异常脂质血症的预防和/或治疗等。
• TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
  申请人：Genentech, Inc.

  公开号：US20160175289A1

  公开（公告）日：2016-06-23

  Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了具有雌激素受体调节活性或功能的四氢-吡啶并[3,4-b]吲哚-1-基化合物，其具有I式结构：以及其立体异构体，互变异构体或药学上可接受的盐，以及所述取代基和结构特征。还描述了包括I式化合物的药物组合物和药物，以及使用这样的雌激素受体调节剂的方法，单独或与其他治疗剂联合治疗介导或依赖于雌激素受体的疾病或病况。